Compare Nuwellis Inc (NUWE) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Virgin Galactic Holdings, Inc. trades at $2.94 (market cap $456.30M). The key difference: Virgin Galactic Holdings, Inc. is far larger — about 207.4× Nuwellis Inc's market cap, and Virgin Galactic Holdings, Inc. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| NUWE | SPCE | |
|---|---|---|
Market Cap | $2.20M | $456.30M |
Volume | 121,544 | 4,518,834 |
Sector | Health | Industrials |
52-Week High | $146.65 | $7.52 |
52-Week Low | $0.68 | $2.17 |
Typical Hold Time | 26 Days | 69 Days |
Enterprise Value | -$1.52M | $420.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
SPCE trades at $2.94, down 4.23% today, reflecting a bearish technical outlook amid persistent fundamental challenges. The company continues to report significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have seen earnings beats. Cash flow remains negative, but trends show improvement, with a projected positive net cash flow of $25M in 2026. Analyst sentiment is mixed, with a Buy/Hold/Sell split of 29%/41%/29%.
The outlook remains high-risk due to ongoing cash burn and delayed commercial flights, but strong ticket demand and a path to positive cash flow by 2027 offer long-term potential. Investors face substantial volatility and dilution risks, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
